https://www.taplowgroup.comInsight
https://www.taplowgroup.comTaplow
https://www.taplowgroup.comKnowledge
  • News
  • Cases
  • Downloads
The Industry Pulse Series (TIPS)
15.11.2021

The Industry Pulse Series (TIPS)

It is a matter of great pleasure and pride that The Taplow Group India has come up with the first issue of The Industry Pulse Series (TIPS)...
Read more
Asia Business Report - October 2021
21.10.2021

Asia Business Report - October 2021

Australian Gross Domestic Product rose by 0.7 percent (seasonally adjusted) in the quarter ending in June 2021. This is being driven by domestic...
Read more
EUROPEAN BUSINESS REPORT September 2021
30.09.2021

EUROPEAN BUSINESS REPORT September 2021

The Taplow Group S.A. with 21 partner firms is located across 6 continents. Our expert consultants bring a wealth of expertise in their respective...
Read more
12345678910Last

 CEO FOR A SPORTS:

Situation: A Finnish, mainly nationally operating sports company needed new CEO as the old one was about to retire. As sports business is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contac Timo Toivanen, Finland

 

 

 CEO FOR LOGISTICS:

Situation: One of the largest globally operating Logistics companies was in a need of new CIO for Finland. As Logistics and Value Chain is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contac Timo Toivanen, Finland

White Papers

  • India – The new R&D hub for Automotive

    Taplow India have conducted an in-depth review of the Automotive sector in India, For further information contact Sangeeta Sabharwal, India

    Click Here

  • Maysam Rizvi reviews the Banking Tech Revolution.

    Capital is more expensive, costs are higher and prices have gone down… the technology revolution has become a necessity.

    Click Here

  • EVOLVING BUSINESS UNITS Market Access thus becoming “transversal”

    The pharmaceutical market, in regards to the price component covered by the NHS, has been, until today, characterised by the presence of drugs of high therapeutic value, such as cancer-drugs, rheumatologic drugs, anti-infection drugs and drugs for the treatment of chronic illnesses, the vast majority of which have either seen their patent expire recently or will see it expire in the next two years.

    Click Here

  • BUSINESS CYCLES

    Present Human Capital Opportunities and Challenges:

    Click Here